Zandecki M, Facon T, Bernardi F, Izydorczyk V, Dupond L, François M, Reade R, Iaru T, Bauters F, Cosson A
Laboratoire d'Hématologie, Hôpital Calmette, Lille, France.
J Clin Pathol. 1995 Jun;48(6):548-52. doi: 10.1136/jcp.48.6.548.
To determine whether a particular phenotype or antigen is preferentially related to monoclonal gammopathies of undetermined significance (MGUS).
Bone marrow specimens from 56 patients with MGUS were stained immunocytochemically (ABC peroxidase) for CD38, CD56, CD9, CD10, CD19, CD20, CD22, and MB2. Specimens from patients recently diagnosed with multiple myeloma and reactive bone marrow samples were studied in parallel.
CD38 was expressed on all plasma cells from all MGUS samples tested, while 36% were positive for CD56, CD9 and MB2 were both expressed strongly; CD20 was moderately expressed, and staining for CD10 and CD22 was uncommon. For these five B cell antigens there was no clear difference between their expression in MGUS and in multiple myeloma. A great difference was found for CD19: in MGUS this antigen was expressed on 2-91% of plasma cells (mean 35%) and 77% patients had > 10% positive plasma cells; in multiple myeloma its expression was low and only 12% patients had > 10% positive plasma cells. When these results were converted to numbers of CD19 positive plasma cells per 100 nucleated bone marrow cells, reactive bone marrow and MGUS specimens had a similar number of positive plasma cells. There was no correlation between expression of any of the antigens tested.
Many of the so-called pre-B, B or activation antigens are present on plasma cells from MGUS specimens, and expression of CD9, CD10, CD20, CD22, MB2, and CD38 in MGUS was very similar to that in multiple myeloma. CD56 was frequently expressed in MGUS. In this series CD19 was highly expressed in MGUS but not in multiple myeloma. Plasma cells bearing this antigen could represent the non-neoplastic process and determination of its expression could be useful for the diagnosis of MGUS.
确定某一特定表型或抗原是否与意义未明的单克隆丙种球蛋白病（MGUS）存在优先关联。
采用免疫细胞化学法（ABC过氧化物酶法）对56例MGUS患者的骨髓标本进行CD38、CD56、CD9、CD10、CD19、CD20、CD22和MB2染色。同时对近期诊断为多发性骨髓瘤患者的标本以及反应性骨髓标本进行平行研究。
在所检测的所有MGUS样本的浆细胞中均表达CD38，36%的样本CD56呈阳性，CD9和MB2均呈强表达；CD20呈中度表达，CD10和CD22染色不常见。对于这五种B细胞抗原，其在MGUS和多发性骨髓瘤中的表达无明显差异。CD19的表达差异很大：在MGUS中，该抗原在2% - 91%的浆细胞中表达（平均35%），77%的患者浆细胞阳性率>10%；在多发性骨髓瘤中其表达较低，仅12%的患者浆细胞阳性率>�10%。当将这些结果换算为每100个有核骨髓细胞中CD19阳性浆细胞的数量时，反应性骨髓和MGUS标本的阳性浆细胞数量相似。所检测的任何抗原的表达之间均无相关性。
许多所谓的前B细胞、B细胞或活化抗原存在于MGUS标本的浆细胞上，MGUS中CD9、CD10、CD20、CD22、MB2和CD38的表达与多发性骨髓瘤非常相似。CD56在MGUS中频繁表达。在本系列研究中，CD19在MGUS中高表达但在多发性骨髓瘤中不表达。携带该抗原的浆细胞可能代表非肿瘤性过程，其表达的测定可能有助于MGUS的诊断。
